| Affiliation: | (1) Department of Medical Oncology, Fudan University Shanghai Cancer center, 270 Dong-An Road, Shanghai, 200032, People’s Republic of China;(2) Department of Pathology, Fudan University Shanghai Cancer center, 270 Dong-An Road, Shanghai, 200032, People’s Republic of China;(3) Department of Oncology, Shanghai Medical Collage, Fudan University, Shanghai, 200032, People’s Republic of China;(4) Department of Oncology, Zhejiang Provincial Cancer Hospital, 38 Guangji Road, Hangzhou, 310022, People’s Republic of China;(5) Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, People’s Republic of China |
| Abstract: | Purpose Nodal peripheral T-cell lymphomas (PTCLs) have particularly poor prognoses. Few data enabling establishment of an accepted standard treatment modality for PTCLs are available. We hypothesized that fludarabine-based regimens are tolerable and effective in treatment for nodal PTCLs. Therefore, this study was to analyze the toxicity of, response rate for, and outcome of treatment for nodal PTCLs with oral fludarabine, doxorubicin, and dexamethasone (FAD). |
